South Korean drugmakers target 200-trillion-won global obesity treatment market

Korean companies broaden obesity-drug investment

South Korean pharmaceutical and biotechnology companies are intensifying their efforts to enter the global obesity-treatment market, which is estimated at roughly 200 trillion won. According to Yonhap News Agency, domestic companies are moving into drug development, manufacturing and contract development and manufacturing, seeking an early position in a market whose commercial potential has been demonstrated by next-generation treatments such as Mounjaro and Wegovy.

The competition extends beyond discovering a proprietary medicine. Korean groups are also examining how to build production capacity and provide CDMO services for other drug developers. This gives companies several possible routes into the market: ownership of a treatment, participation in its manufacturing, or a combination of development and production services. The breadth of activity shows that the opportunity is being assessed across the pharmaceutical value chain rather than only by research-focused biotechnology businesses.

Mounjaro and Wegovy establish the commercial benchmark

The high profitability of Mounjaro and Wegovy has strengthened industry interest in the GLP-1 category. Their performance provides Korean companies with evidence that obesity medicines can support a large global market, while also setting a demanding benchmark for new entrants. Developers must compete in a field where established products have already secured recognition, and manufacturers must demonstrate that they can support complex, commercially significant programs.

For Korean pharmaceutical and biotech companies, the strategic question is therefore not simply whether demand exists. It is where they can capture value. A proprietary obesity treatment offers the greatest direct exposure to product sales but requires successful development. Manufacturing and CDMO activity can provide another point of entry by serving companies that need development support or production capacity. Pursuing several approaches may also allow larger groups to use existing research and manufacturing capabilities across multiple projects.

Competition shifts toward development and production execution

Yonhap describes the domestic contest as a race to secure an early share of a market regarded as a major profit opportunity. That competition is likely to be shaped by companies’ ability to move programs through development and establish reliable manufacturing operations. Announcing entry into obesity treatment is only the first step; commercial participation depends on turning research projects and capacity plans into products or contracted production.

The roughly 200-trillion-won estimate explains why both pharmaceutical manufacturers and biotech developers are committing resources despite competition from established medicines. The market is large enough to attract companies with different business models, from proprietary drug development to outsourced manufacturing. It also creates a potential industrial opportunity for South Korea: successful domestic programs could give the country a larger role in a fast-growing segment of global pharmaceutical production.

Multiple entry routes create different risks

The development route carries the uncertainty inherent in bringing a new treatment forward, while the CDMO route depends on winning and executing contracts. Production investment also requires companies to judge future demand and the capacity needed to serve it. These choices will determine which Korean businesses gain meaningful exposure to the market and which remain at the investment stage.

For producers, investors and pharmaceutical-sector analysts, the next indicators will be concrete development progress, manufacturing commitments and CDMO agreements. The success of Mounjaro and Wegovy has established the attraction of the category. Korean companies must now show whether their development pipelines and production strategies can convert that attraction into a durable commercial position.